Key result
SGLT-2 inhibitors significantly improved flow-mediated dilation compared to control groups in patients with type 2 diabetes (SMD 0.18), but had no significant effect on pulse wave velocity.
Why the study?
This study aimed to evaluate the effects of SGLT-2 inhibitors on endothelial function and arteriosclerosis or arterial stiffness in patients with type 2 diabetes.
Do SGLT-2 inhibitors improve vascular endothelial function and arterial stiffness in patients with type 2 diabetes?
Meta-Analysis (n=868)
Do SGLT-2 inhibitors improve vascular endothelial function and arterial stiffness in patients with type 2 diabetes?
Standardized Mean Difference: 0.18 (95% CI 0.02–0.34)
p-value: p=0.03
SGLT-2 inhibitors significantly improve arterial endothelial function (FMD) in patients with type 2 diabetes, though they do not significantly affect arterial stiffness (PWV).
No takes yet. Share an insight, caveat, or question.
Supports SGLT-2 inhibitor use to improve endothelial function in type 2 diabetes; extends meta-analytic evidence on selective vascular effects.
Wei et al. (2022) conducted a meta-analysis in Type 2 Diabetes (n=868). SGLT-2 inhibitors vs. Control (metformin, sulfonylureas, GLP-1, placebo) was evaluated on Flow-mediated dilation (FMD) (SMD 0.18, 95% CI 0.02-0.34, p=0.03). SGLT-2 inhibitors significantly improved flow-mediated dilation compared to control groups in patients with type 2 diabetes (SMD 0.18), but had no significant effect on pulse wave velocity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: